News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Grant Ventures, Inc. (GRTV) To Present At Rodman & Renshaw Techvest 6th Annual Healthcare Conference


10/19/2005 5:11:54 PM

SALT LAKE CITY, Oct. 22 /PRNewswire-FirstCall/ -- Grant Ventures, Inc., (BULLETIN BOARD: GRTV) announced today that the company will be presenting at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference at the Waldorf Astoria Hotel, 301 Park Avenue, New York, NY. Mr. Stan Yakatan, CEO and President of Grant Life Sciences, will provide an overview of the company and an update on clinical and business activities.

Mr. Stan Yakatan will present at 12:45 p.m. (ET) on Wednesday, October 27, 2004. A live audio webcast will be available during the presentation at http://www.wsw.com/webcast/rrshq4/grtv.ob and will be archived for a period of 90 days.

About Grant Ventures, Inc.

Grant Ventures, Inc. develops products to improve the efficiency of diagnosing cervical cancer. The Company currently is developing protein-based screening tests to screen woman for cervical cancer and pre-cancerous conditions. This screening test analyzes blood for the presence of certain antibodies that appear only when cervical cancer or certain pre-cancerous conditions are present. Invasive cervical cancer kills approximately 300,000 women annually. Currently, there are more than 120 million cervical screening tests administered annually in the United States and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears and globally 1.7 billion women over the age of 20 do not undergo regular cervical cancer testing.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see our filings with the Securities and Exchange Commission.

Grant Ventures, Inc.

CONTACT: Stan Yakatan, Chief Executive Officer, Grant Ventures, Inc.,+1-310-374-0808; or Brian Korb, Senior Associate, The Trout Group,+1-212-477-9007, ext. 23


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES